The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
|Podcasts|March 7, 2023
Applying the Latest Evidence to Delay the Onset of Type 1 Diabetes
Hosts Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP-BC, interview Emily Sims, MD, to discuss the latest clinical evidence on teplizumab and other emerging treatments that can delay the onset of type 1 diabetes.
Advertisement
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
New ASH guidelines recommend higher ferritin thresholds to improve the diagnosis of iron deficiency across key populations.
In this Q&A, Alysse Wurcel, MD, translates qualitative barriers into 8 concrete tactics healthcare practices can use to expand penicillin allergy delabeling.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.
Wuyts, of University Hospitals Leuven discusses interim FIBRONEER-ON open-label extension data showing nerandomilast's favorable safety profile.
Advertisement
Advertisement
Trending on HCPLive
1
Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD
2
ASH Issues New Ferritin Thresholds for Iron Deficiency Diagnosis
3
Immediate Coronary Angiography Does Not Improve Survival Outcomes in Cardiac Arrest
4
Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data
5